PT  - JOURNAL ARTICLE
AU  - Kobina K. Hagan
AU  - Zulqarnain Javed
AU  - Isaac Acquah
AU  - Tamer Yahya
AU  - Javier Valero-Elizondo
AU  - Adnan A. Hyder
AU  - Elias Mossiolas
AU  - Shubham Lahan
AU  - Miguel Cainzos-Achirica
AU  - Khurram Nasir
TI  - Atherosclerotic Cardiovascular Disease and Health-Related Quality of Life Among Adults in the United States: National Health Interview Survey 2013-2017
AID  - 10.1101/2022.08.31.22279420
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.31.22279420
4099  - http://medrxiv.org/content/early/2022/09/01/2022.08.31.22279420.short
4100  - http://medrxiv.org/content/early/2022/09/01/2022.08.31.22279420.full
AB  - Background A brief health-related quality of life (HRQoL) tool with construct validity for atherosclerotic cardiovascular disease (ASCVD) may facilitate integration into healthcare delivery. We examined ASCVD-related changes in the Health and Activity Limitation Index (HALex), a generic HRQoL measure comprising perceived health and activity limitation.Methods Using data of 155,130 respondents of the National Health Interview Survey 2013-2017, we evaluated HALex scores by ASCVD (angina, heart attack, and stroke). Lower HALex scores reflected worse HRQoL and a 0.03 change was regarded as the threshold for clinical significance. Multivariable two-part models were used to assess HALex changes (β, 95%CI) associated with ASCVD overall and in sex, age, and race/ethnicity groups.Results Overall, participants with ASCVD – 6.8%, representing 15.7 million adults – had lower HALex scores (0.67) than those without ASCVD (0.87). Females, age ≥ 65 years, and non-Hispanic Blacks had the lowest HALex scores. Overall, ASCVD was associated with a substantial decrement in HALex (−0.10, [−0.10, −0.09]). Interactions between ASCVD and sex, and race/ethnicity were both significant (p < 0.001). ASCVD-associated decrement in HALex was clinically greater in: females (−0.11, [−0.12, −0.10]) than in males (−0.08, [−0.09, −0.07]); and non-Hispanic Black (−0.13, [−0.15, −0.1]) than in non-Hispanic White (−0.09, [−0.10, −0.08]). Though ASCVD impact on HALex was greater in age 18-64 years (−0.09, [−0.10, −0.08]), it was not statistically different from the elderly (−0.06, [−0.07, −0.06]).Conclusions ASCVD was consistently associated with lower HRQoL, as measured by HALex, across major demographics. HALex presents a feasible HRQoL tool to implement in healthcare.Competing Interest Statement KN is on the advisory board of Amgen and Novartis, and his research is partly supported by the Jerold B. Katz Academy of Translational Research. KN and MCA are on the Steering Committee of the PAK-SEHAT Study, partially funded by an unrestricted research grant from Getz Pharma. AAH declares current funding from the United States National Institutes of Health, the World Bank, and the World Health Organization. The other authors report no conflicts of interest relevant to this work.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National Health Interview Survey data files are deidentified and publicly available on the Centers for Disease Control and Prevention's National Center for Health Statistics web page (https://www.cdc.gov/nchs/nhis/1997-2018.htm)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.cdc.gov/nchs/nhis/1997-2018.htm ASCVDatherosclerotic cardiovascular diseaseCOPDchronic obstructive pulmonary diseaseGEDGeneral Educational DevelopmentHALexHealth and Activity Limitation IndexHRQoLhealth-related quality of lifeNHISNational Health Interview SurveyORodds ratioPROMpatient-reported outcome measuresSEstandard error